Pfizer Inc. (PFE)

42.33
0.24 0.57
NYSE : Health Technology
Prev Close 42.09
Open 42.20
Day Low/High 42.09 / 42.77
52 Wk Low/High 32.32 / 42.19
Volume 21.20M
Avg Volume 19.58M
Exchange NYSE
Shares Outstanding 5.86B
Market Cap 242.81B
EPS 3.60
P/E Ratio 11.07
Div & Yield 1.36 (3.21%)

Latest News

Investors May Have Omarosa to Thank for Pretty Good Week

Investors May Have Omarosa to Thank for Pretty Good Week

Thanks, Omarosa. And you too, Bob Mueller, for distracting the president this week from trade wars and tariff skirmishes and allowing investors to make some money.

Walmart Fuels Monster Move: Cramer's 'Mad Money' Recap (Thursday 8/16/18)

Walmart Fuels Monster Move: Cramer's 'Mad Money' Recap (Thursday 8/16/18)

Walmart -- with great growth -- sparks optimism, but Jim Cramer says it's not the only stock to fuel the day's rally.

Walmart's Assault on Amazon Looks as if It's Starting to Pay Off in a Big Way

Walmart's Assault on Amazon Looks as if It's Starting to Pay Off in a Big Way

Retail earnings are in full swing with results from Walmart and J.C. Penney. All eyes still on the cannabis space. Big day for tool king Stanley Black & Decker.

Buy Stocks That Are Down, Not Up, Here

Buy Stocks That Are Down, Not Up, Here

Take a pass on stocks like Kimberly-Clark or Pfizer that are bucking Wednesday's sell-off and going higher.

Why One Money Manager Is Telling Clients to Raise Cash Right Now

Why One Money Manager Is Telling Clients to Raise Cash Right Now

Time to brace for a summer pullback?

3 Cheap Healthcare Stocks That Won't Make Your Portfolio Sick

3 Cheap Healthcare Stocks That Won't Make Your Portfolio Sick

The healthcare space continues to be ripe for investment opportunity. Here are three stocks that won't make your portfolio sick.

Pfizer Becomes #12 Most Shorted Dow Stock, Replacing Coca-Cola

Pfizer Becomes #12 Most Shorted Dow Stock, Replacing Coca-Cola

The most recent short interest data has been released for the 07/31/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Healthcare Bulls Are Feeling Great After Earnings

Healthcare Bulls Are Feeling Great After Earnings

Investors may have been betting that the 'drug pricing war' was a non-event and that the upcoming earnings cycle would show continued growth and profitability in the healthcare sector.

XELJANZ® (tofacitinib Citrate) Receives Marketing Authorization In The European Union For Moderately To Severely Active Ulcerative Colitis

XELJANZ® (tofacitinib Citrate) Receives Marketing Authorization In The European Union For Moderately To Severely Active Ulcerative Colitis

Pfizer Inc. (NYSE:PFE) announced today that the European Commission (EC) has approved XELJANZ ® (tofacitinib citrate) 10 mg twice-daily (BID) for at least eight weeks, followed by XELJANZ 5 mg BID or 10 mg BID, for the treatment of adult patients with...

Dow, Nasdaq and S&P 500 End Higher on Tech Rebound

Dow, Nasdaq and S&P 500 End Higher on Tech Rebound

Major indexes gave ground in the final minutes of trade, but managed to stay in positive territory at the close.

Best Tech Stocks to Buy -- No Matter What Apple Reports

Best Tech Stocks to Buy -- No Matter What Apple Reports

Tech is still the equity market's leading sector over three months -- and over most timeframes going back years.

Global Stocks Mixed Amid Extended Tech Woes; BoJ Moves Boost Bond Markets

Global Stocks Mixed Amid Extended Tech Woes; BoJ Moves Boost Bond Markets

Global stocks continued to edge lower Tuesday, as tech sector weakness bled into markets in Asia following last night's sell off on Wall Street, putting even more pressure on today's third quarter earnings report from Apple at the close of trading today.

PFIZER REPORTS SECOND-QUARTER 2018 RESULTS

PFIZER REPORTS SECOND-QUARTER 2018 RESULTS

Pfizer Inc. (NYSE: PFE) reported financial results for second-quarter 2018 and raised 2018 financial guidance for Adjusted diluted EPS (2).

Apple, Federal Reserve, Pfizer, General Electric, CBS - 5 Things You Must Know

Apple, Federal Reserve, Pfizer, General Electric, CBS - 5 Things You Must Know

U.S. stock futures are rising slightly on Tuesday ahead of earnings from Apple and as a two-day meeting of the Federal Reserve gets set to begin.

Pfizer Receives European Approval For Oncology Biosimilar, TRAZIMERA™ (trastuzumab)

Pfizer Receives European Approval For Oncology Biosimilar, TRAZIMERA™ (trastuzumab)

Pfizer Inc. (NYSE:PFE) today announced the European Commission (EC) has approved TRAZIMERA™, 1 a biosimilar to Herceptin ®* (trastuzumab), for the treatment of human epidermal growth factor (HER2) overexpressing breast cancer and HER2 overexpressing...

Pfizer's New Report Shows How Behavioural Science Can Help Boost Preventative Healthcare Measures

Pfizer's New Report Shows How Behavioural Science Can Help Boost Preventative Healthcare Measures

PARIS, July 31, 2018 /PRNewswire/ -- Released today, a new report based on research by the Economist Intelligence Unit (EIU) and sponsored by Pfizer Vaccines assesses why, despite the evidence supporting the medical and cost-saving benefits of...

Dow Ends Near Day's Lows as Tech Slump Hits Shares

Dow Ends Near Day's Lows as Tech Slump Hits Shares

Stocks ended lower on weakness in tech shares and after a strong report from Caterpillar proved insufficient to prop up the Dow.

Jim Cramer: How to Pick Stocks When the Market Is Flying Blind

Jim Cramer: How to Pick Stocks When the Market Is Flying Blind

This market clearly has no clue what to buy, with strong GDP growth but challenging trade dynamics and the Facebook and Twitter bombs last week.

Earnings On Pace For Most 'Beats' in a Decade as Tariffs Pose Few Concerns

Earnings On Pace For Most 'Beats' in a Decade as Tariffs Pose Few Concerns

U.S. companies are on pace for one of the best earnings seasons in a decade, according to mid-term data from FactSet, with most firms appearing to have little or no concern for the impact of trade and tariffs on their bottoms lines over the coming months.

Merck Beats Estimates and Raises Guidance, But Stock Plops 2%

Merck Beats Estimates and Raises Guidance, But Stock Plops 2%

Shares fell on Friday morning despite positive results for the second quarter.

The Race to Cure Alzheimer's is On: These Are the Forerunners

The Race to Cure Alzheimer's is On: These Are the Forerunners

Top pharmaceutical companies are paving the way to a cure for Alzheimer's, a degenerative disease that is affecting millions around the world.

Biogen's Big Alzheimer's Presentation on Wednesday: What You Need to Know

Biogen's Big Alzheimer's Presentation on Wednesday: What You Need to Know

The biotech giant will present detailed results of its mid-stage trials of BAN2401 at the Alzheimer's Association International Conference in Chicago.

ViiV Healthcare Announces SWORD 100-week Data For Juluca (dolutegravir/rilpivirine) At AIDS 2018

ViiV Healthcare Announces SWORD 100-week Data For Juluca (dolutegravir/rilpivirine) At AIDS 2018

ViiV Healthcare today presented 100-week results from its phase III programme evaluating the safety and efficacy of switching virologically-suppressed people living with HIV (PLHIV) from a three or four-drug antiretroviral regimen to a 2-drug regimen of...

ViiV Healthcare Presents Phase III Data At AIDS 2018 From Landmark GEMINI Studies Showing Two-Drug Regimen Of Dolutegravir And Lamivudine Has Similar Efficacy To A Three-Drug Regimen In Treatment Naïve HIV Patients, With No Emergence Of Resistance

ViiV Healthcare Presents Phase III Data At AIDS 2018 From Landmark GEMINI Studies Showing Two-Drug Regimen Of Dolutegravir And Lamivudine Has Similar Efficacy To A Three-Drug Regimen In Treatment Naïve HIV Patients, With No Emergence Of Resistance

ViiV Healthcare today presented at the 22 nd International AIDS conference in Amsterdam 48-week results from the phase III GEMINI 1 & 2 studies, assessing the safety and efficacy of a two-drug regimen (2DR) of dolutegravir (DTG) and lamivudine (3TC)...

Broker Darlings Of The Dow: Pfizer Ranks As A Top 15 Analyst Pick

Broker Darlings Of The Dow: Pfizer Ranks As A Top 15 Analyst Pick

A study of analyst recommendations at the major brokerages shows that Pfizer Inc is the #10 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Pfizer Inc also comes in above the median of analyst picks among the broader S&P 500 index components, claiming the #110 spot out of 500.

4 Conservative Dividend Stocks That Belong in Every Income Investors Portfolio

4 Conservative Dividend Stocks That Belong in Every Income Investors Portfolio

These blue chips pay shareholders handsomely in the form of dividends and share buybacks.

Using Technical Analysis to Profit: Cramer's 'Mad Money' Recap (Friday 7/20/18)

Using Technical Analysis to Profit: Cramer's 'Mad Money' Recap (Friday 7/20/18)

Why study charts? Because they're like footprints at the scene of the crime, clues to what the big money managers are likely thinking, Jim Cramer says.

TheStreet Quant Rating: A (Buy)